Blood test to predict bleeding risk after procedures in cirrhosis
Part of Digestive system clinical trials.
This trial is testing if a special blood test called ROTEM can help doctors predict the risk of bleeding after high-risk procedures in people with cirrhosis. It aims to improve safety and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with cirrhosis (scarring of the liver).
- You are scheduled for a high-risk procedure (like a biopsy or other invasive test).
- Your platelet count is very low (below 50,000) or your INR (a blood clotting test) is above 1.5 with a low platelet count (below 100,000).
- You are not currently in the hospital for severe liver failure or in the intensive care unit.
- You do not have advanced kidney disease, a history of blood clots, cancer outside the liver, or a blood disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two tests (ROTEM and TEG) that help doctors decide which blood products to give to cirrhosis patients with active stomach or intestinal bleeding that is not from varices. The goal is to find which test works better.
This trial tests whether using a slightly different target on a blood-clotting test (ROTEM) can reduce the need for blood transfusions in people with liver disease who need a procedure. If you have cirrhosis or ACLF with severe clotting problems, this study may help your doctors decide how much blood product to give you before the procedure.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This trial studies bleeding problems in people with advanced liver cirrhosis or liver cancer. It aims to improve understanding of when blood transfusions or treatments are needed.
This study compares a special blood test (thrombelastometry) to standard tests to decide when to give blood products before invasive procedures in people with advanced liver cirrhosis. The goal is to see which method leads to better use of blood products and fewer complications.
This trial compares how well an artificial intelligence (AI) tool interprets ROTEM blood-clotting tests compared to human experts. The results could help doctors make faster and more accurate decisions about bleeding or clotting problems.
Hear when a new Cirrhosis, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.